ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
31 hedge funds and large institutions have $1.43M invested in ImmunoCellular Therapeutics, Ltd. in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 7 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
14% less funds holding
Funds holding: 36 → 31 (-5)
49% less capital invested
Capital invested by funds: $2.77M → $1.43M (-$1.34M)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$314K |
| 2 |
Renaissance Technologies
New York
|
+$133K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
+$8.04K |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$6.68K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$3.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Bailard
Foster City,
California
|
-$518K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$75.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10K |
| 4 |
Bank of New York Mellon
New York
|
-$5.55K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$5K |
IMUC Hedge Fund Activity: Q3 2016 in Review
31 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q3 2016, worth a combined $1.43M — down 49% from $2.77M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IMUC and 2 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Sabby Management, adding an estimated $314K. The largest seller was Bailard, exiting entirely with an estimated $518K sold.
- 31 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q3 2016, down from 36 in Q2 2016.
- Funds reported $1.43M of ImmunoCellular Therapeutics, Ltd. stock for Q3 2016, down 49% quarter-over-quarter.
- 2 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q3 2016 and 7 closed out, a net change of -5 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q3 2016 was Sabby Management, an estimated $314K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q3 2016 was Bailard, an estimated $518K sold.
Based on aggregated 13F filings for Q3 2016.